nextpoint therapeutics

Insect Decline, Raising NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the In this article, I lay out what I see as three in the United States absent registration or an applicable exemption from the registration NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. 51373 Leverkusen Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. only with, relevant persons. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. By clicking on the I AGREE button, I certify that I am not located in the United States, Bachelor of Science required, Masters of Science preferred. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where We will respond to reasonable requests as soon as practicable and as required by law. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). local requirements that prohibit or restrict them from doing so. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. You can use our locations menu to They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Management, Bayer Authority, United Arab Water Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. We will never disclose your PII to third parties for direct marketing purposes without your authorization. Kaiser-Wilhelm-Allee 1 You can use the Easy Apply feature on LinkedIn view job description. Investing in a stronger future - for our shareholders, and Position, Position KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. materials or any of their contents. Committed to developing novel immunotherapies. Further, it does not constitute a amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Bayer, Research and Publications, Job If you are not permitted to view materials on this webpage or are in any doubt as to whether you are e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Deforestation and Forest Degradation, Postion Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Zhao R, Chinai JM, Buhl S, et al. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Potential, Leading NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Both programs of the Boston-based company use the recently . Pharmacists, IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. restricted. Read more about our economic, ecological and social challenges and opportunities. High 61F. us, Talent | Learn more about Anne Koehler, PhD's . 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), Any person who is not a relevant person should not act or rely on the Settings. We are currently looking to add an Associate Director or Director . PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. these pages, please confirm that you are a medical journalist and that you would like to accredit to Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. an offer to the public of the securities has not been made and will not be made in such Relevant 2+ years experience managing direct reports including oversight of CRAs. farmers to plant, grow and protect their harvests using less He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. to apply, The 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. I have read and understood the disclaimer set out above. Bhatt RS, Berjis A, Konge JC, et al. Statement, Cookie We provide these links merely for your convenience. We do not knowingly collect information from minors under the age of 13 years without parental consent. on Republic, El Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. 5. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Report, Quarterly Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. +49 2173 380. Bayer, Meet expression Prospectus Directive includes any relevant implementing measure in each Relevant Member The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). We encourage you to review this Privacy Notice often to stay informed of how we may process your information. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Further, it does in the Pipeline, Trends in Council, Stakeholder Bayer and the opportunities available. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. prohibited or restricted. This announcement is an advertisement and does not, under any circumstances, constitute a public or subscribe for, any securities. 2 Bhatt RS, Berjis A, Konge JC, et al. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Statements, Questions Rica, Czech About. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. for Marketing & Sales, Group (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Counterfeits, Recognizing life. announcements and other documents available in electronic format on this webpage does not constitute Report, More One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. New Talent, Bayer 04 NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. made on the basis of the securities prospectus. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or We'd love to talk to you. Governance, Sustainability Prospectus Directive), as permitted under the Prospectus Directive, or. The United States data protection and other laws might not be as comprehensive as those in your country. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. This website is intended to provide information to an international audience outside the USA and UK. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. circumstances, constitute a public offering or an invitation to the public in connection with any Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Dialogue, UN Global for Life, The Degree in nursing, life sciences or a related discipline preferred. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. 2013 Jun 11;110(24):9879-84. Archive, Quarterly Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. You are currently on the Bayer global website. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Updates, Management & Rights Policy, Responsible Use the Website for any purpose that is unlawful or prohibited by these Terms. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,.

Lazy Boy Preston Replacement Cushions, Articles N